Advanced Biomed (NASDAQ:ADVB) Issues Earnings Results

Advanced Biomed (NASDAQ:ADVB) posted its earnings results on Thursday. The company reported ($0.60) EPS for the quarter, FiscalAI reports.

Advanced Biomed Stock Performance

ADVB opened at $3.00 on Friday. The firm has a market cap of $4.95 million, a P/E ratio of 0.62 and a beta of 0.69. The business has a 50 day moving average price of $5.25 and a 200 day moving average price of $5.74. Advanced Biomed has a twelve month low of $1.80 and a twelve month high of $24.23.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on ADVB shares. Wall Street Zen lowered shares of Advanced Biomed from a “hold” rating to a “sell” rating in a research note on Saturday, October 17th. Weiss Ratings downgraded shares of Advanced Biomed from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, October 8th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

About Advanced Biomed

Our Mission We are committed to the application research of integrating semiconductor technology and biotechnology. Through the enrichment, capture, and identification of circulating tumor cells and related tumor marker cells in the field of liquid biopsy, we aim to provide cancer patients with rapid and affordable assay products and services. These services include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer. We are a holding company incorporated in the State of Nevada.